Inhibition of LAIR1 signaling has been shown to render resistant cancer cells more susceptible to anti-PD-1/PD-L1 therapy [19, 20], indicating that LAIR1 may serve as a potential biomarker for cancer immunotherapy. This evidence concerns the gene PDCD1 and cancer.